Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 177

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission

Open access
Piel, Frédéric B, Rees, David C, DeBaun, Michael R, Nnodu, Obiageli, Ranque, Brigitte, Thompson, Alexis A, Ware, Russell E, Abboud, Miguel R, Abraham, Allistair, Ambrose, Emmanuela E, Andemariam, Biree, Colah, Roshan, Colombatti, Raffaella, Conran, Nicola, Costa, Fernando F, Cronin, Robert M, de Montalembert, Mariane, Elion, Jacques, Esrick, Erica, Greenway, Anthea L, Idris, Ibrahim M, Issom, David-Zacharie, Jain, Dipty, Jordan, Lori C, Kaplan, Zane S, King, Allison A, Lloyd-Puryear, Michele, Oppong, Samuel A, Sharma, Akshay, Sung, Lillian, Tshilolo, Leon, Wilkie, Diana J, Ohene-Frempong, Kwaku · 2023 · The Lancet Haematology

Abstract

Executive summary All over the world, people with sickle cell disease (an inherited condition) have premature deaths and preventable severe chronic complications, which considerably affect their quality of life, career progression, and financial status. In addition, these people are often affected by stigmatisation or structural racism, which can contribute to stress and poor mental health. Inequalities affecting people with sickle cell disease are also reflected in the distribution of the disease—mainly in sub-Saharan Africa, India, and the Caribbean—whereas interventions, clinical trials, and funding are mostly available in North America, Europe, and the Middle East. Although some of these characteristics also affect people with other genetic diseases, the fate of people with sickle cell disease seems to be particularly unfair. Simple, effective interventions to reduce the mortality and morbidity associated with sickle cell disease are available. The main obstacle preventing better outcomes in this condition, which is a neglected disease, is associated with inequalities impacting the patient populations. The aim of this Commission is to highlight the problems associated with sickle cell disease and to identify achievable goals to improve outcomes both in the short and long term. The ambition for the management of people with sickle cell disease is that curative treatments become available to every person with the condition. Although this would have seemed unrealistic a decade ago, developments in gene therapy make this potentially achievable, albeit in the distant future. Until these curative technologies are fully developed and become widely available, health-care professionals (with the support of policy makers, funders, etc) should make sure that a minimum standard of care (including screening, prophylaxis against infection, acute medical care, safe blood transfusion, and hydroxyurea) is available to all patients. In considering what needs to be achieved to reduce the global burden of sickle cell disease and improve the quality of life of patients, this Commission focuses on five key areas: the epidemiology of sickle cell disease (Section 1); screening and prevention (Section 2); established and emerging treatments for the management of the disease (Section 3); cellular therapies with curative potential (Section 4); and training and education needs (Section 5). As clinicians, researchers, and patients, our objective to reduce the global burden of sickle cell disease aligns with wider public health aims to reduce inequalities, improve health for all, and develop personalised treatment options. We have observed in the past few years some long-awaited momentum following the development of innovative point-of-care testing devices, new approved drugs, and emerging curative options. Reducing the burden of sickle cell disease will require substantial financial and political commitment, but it will impact the lives of millions of patients and families worldwide and the lessons learned in achieving this goal would unarguably benefit society as a whole.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(23)00096-0

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Metadata

Authors
Piel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., Andemariam, B., Colah, R., Colombatti, R., Conran, N., Costa, F. F., Cronin, R. M., de Montalembert, M., Elion, J., Esrick, E., Greenway, A. L., Idris, I. M., Issom, D.-Z., Jain, D., Jordan, L. C., Kaplan, Z. S., King, A. A., Lloyd-Puryear, M., Oppong, S. A., Sharma, A., Sung, L., Tshilolo, L., Wilkie, D. J., & Ohene-Frempong, K.
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2023-08
Volume
10
Issue
8
Pages
e633-e686
ISSN
2352-3026 (ISSN-L)
OpenAlex
W4383874164
Cited by
177
References
52
FWCI
25.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. https://app.cochat.ai/papers/10.1016/s2352-3026(23)00096-0
The paper
Piel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., Andemariam, B., Colah, R., Colombatti, R., Conran, N., Costa, F. F., Cronin, R. M., de Montalembert, M., Elion, J., Esrick, E., . . . Ohene-Frempong, K. (2023). Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(23)00096-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.